$995 | Single User
$1990 | Site License
$2495 | Global License

Hepatitis C: Update Bulletin
[February 2016]
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2016 | 307 | In Stock

Introduction

Introduction


Gain new KOL insights on the latest events that have the potential to shape the hepatitis C virus (HCV) treatment landscape. Topics covered include KOL insights on how Merck & Co.’s Zepatier (elbasvir and grazoprevir) is likely to be used as a treatment for HCV, and if the additional testing requirements could slow down adoption; what KOLs think of AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with a dasabuvir tablet) now being approved without the need for ribavirin; reaction to data from the ASTRAL trial for Gilead’s sofosbuvir with velpatasvir, and if the data could provide Gilead with an edge in the GT3 HCV treatment space; thoughts on the potential impact of adding GS9857 to Gilead’s sofosbuvir and velpatasvir, and if a short treatment regimen is attractive to KOLs.


Key Questions Answered in this Update Bulletin:


  • How do KOLs expect Merck & Co.’s Zepatier (elbasvir and grazoprevir) to be received in the marketplace, and does being indicated in renally impaired patients give it an edge?

  • Are KOLs at all concerned about the additional testing recommendations associated with using Zepatier in certain patient populations, and could Zepatier be used ‘off-label’ in GT3 patients in the US?

  • Do KOLs have any concerns about AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with a dasabuvir tablet) now being approved for use without the need for ribavirin, and will this impact usage?

  • Are KOLs at all concerned about the safety signals observed in the TURQUOISE trial for Viekira Pak, and do KOLs anticipate this revised treatment regimen having a long-standing impact on the hepatitis C market?

  • How do KOLs perceive the data from Gilead’s ASTRAL clinical trial programme, and do they have any reservations about using sofosbuvir with velpatasvir, particularly in GT3 HCV patients?

  • What impact do KOLs believe the addition of GS9857 to sofosbuvir and velpatasvir will have on its use in the HCV treatment paradigm, and will the appeal of a shorter treatment duration of eight weeks give the therapy combination a significant edge in the marketplace?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

    Table of Contents
    for Hepatitis C: Update Bulletin [February 2016] [Published by FirstWord Pharma]

    • -

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    307 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Hepatitis Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015
    Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report...
    16 Dec 2015 by Global Data USD $2,500 More Info
    Hepatitis C: KOL Insight
    IntroductionThe Hepatitis C (HCV) market will be driven by meeting the needs of under-served patient...
    01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
    Physician Views: The hepatitis C pricing war - what impact on prescribers?
    Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
    29 Jan 2015 by FirstWord Pharma USD $695 More Info
    Payer Insights: Hepatitis C
    IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
    26 Sep 2014 by FirstWord Pharma USD $7,900 More Info
    Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?
    Scope Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tr...
    08 Jul 2014 by FirstWord Pharma USD $695 More Info
    Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?
    Scope With this year's meeting of the International Liver Congress (EASL) just over a week away (Apr...
    01 Apr 2014 by FirstWord Pharma USD $695 More Info
    Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
    IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
    01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
    Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?
    Scope Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, inter...
    01 Nov 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?
    ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
    01 Oct 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Hepatitis C: Update Bulletin [February 2016] [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...